Panacea Biotec launches Oncology product ‘CABAPAN’

28 Mar 2016 Evaluate

Panacea Biotec, India's 3rd largest biotechnology company has introduced indigenously developed high quality Oncology product -- CABAPAN (Cabazitaxel Injection), for treatment of metastatic Castration Resistant Prostrate Cancer (mCRPC).

Prostate is the second leading site of cancer amongst males with rising mortality rate in India. With ever changing lifestyles, increased awareness, better diagnostic techniques and increased accessibility to medical treatment, more cases of Ca Prostate are being diagnosed.

CABAPAN has been developed by the company's state of the art Global Research and Development Center (GRAND), Mumbai and manufactured at modern production facility complying with global current Good Manufacturing Practices (cGMP), at Baddi, Himachal Pradesh.

Panacea Biotec is the third largest biotechnology company as well as among the top 50 pharmaceutical companies of India. The company has product portfolio that’s caters therapeutics areas like pain management, diabetes and cardiovascular management, renal disease management, osteoporosis management, anti-tubercular, gastro-intestinal.

Panacea Biotec Share Price

557.60 -6.05 (-1.07%)
30-Apr-2025 09:37 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1824.75
Dr. Reddys Lab 1193.65
Cipla 1564.80
Lupin 2103.85
Zydus Lifesciences 899.60
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...